Home/Pipeline/Internal Solid Tumor Program(s)

Internal Solid Tumor Program(s)

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Chimera Bioengineering

About Chimera Bioengineering

Chimera Bioengineering is pioneering a novel approach to cell therapy by developing CAR-T cells with precisely controlled genetic programming. Their core technology, the GOLD PLATFORM™, includes components like MERCURY™ for tuning CAR expression and GOLD CONTROL™ for regulating therapeutic payloads, addressing key challenges of insufficient activity and excessive toxicity in current cell therapies. The company is independently advancing several solid tumor and blood cancer programs toward clinical trials while seeking strategic collaborations to validate and expand its platform. Their mission is to transform the promise of cell therapies into effective, safe treatments that restore dignity to cancer patients.

View full company profile

Therapeutic Areas

Oncology Solid Tumors Blood Cancers

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed